ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Raptor Pharmaceutical Corp. (RPTP) Report Updated: Jun 17, 2013 | Print This Page

Get more stock ratings by Louis Navellier

Raptor Pharmaceutical Corp. (RPTP)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Biotechnology
Competitors: NPSP, TKMR, PBYI, MDXG
hide

Stock Analysis

Rating: Monthly View

A
B
C
D
F
June July August September October November December January February March April May

Rating: Weekly View

This Week: C down downgrade
Last Week: B same no change
Two Weeks Ago: B up upgrade
service keys
hide

Raptor Pharmaceutical Corp.© quotemedia

hide

Company Profile

Raptor Pharmaceuticals Corp. operates as a biotechnology company in the United States. The company is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Its clinical stage development products include DR Cysteamine, which is in phase IIb for the treatment of cystinosis; phase IIa for the non-alcoholic steatohepatitis; and phase II for the treatment of Huntington’s disease. Raptor’s clinical-stage products also include Convivia that is in Phase IIa stage for the potential management of acetaldehyde toxicity due to alcohol consumption; and Tezampanel and NGX 426, which completed phase I stage for the treatment of migraine and pain. Its preclinical product candidates comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis; WntTide for the treatment of breast cancer; NeuroTrans for the treatment of neurodegenerative diseases; and Tezampanel and NGX 426 for the treatment of Thrombosis and Spasticity Disorder. Raptor Pharmaceuticals Corp. is headquartered in Novato, California.